X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PIRAMAL ENTERPRISES ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 157.6 11.1 1,420.1% View Chart
P/BV x 24.5 1.9 1,280.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 ASTRAZENECA PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
PIRAMAL ENTERPRISES
Mar-18
ASTRAZENECA PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2853,083 41.7%   
Low Rs6341,902 33.3%   
Sales per share (Unadj.) Rs189.6589.7 32.1%  
Earnings per share (Unadj.) Rs-0.2284.0 -0.1%  
Cash flow per share (Unadj.) Rs3.8310.5 1.2%  
Dividends per share (Unadj.) Rs025.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs68.61,467.0 4.7%  
Shares outstanding (eoy) m25.00180.27 13.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x5.14.2 119.7%   
Avg P/E ratio x-4,712.78.8 -53,702.4%  
P/CF ratio (eoy) x249.68.0 3,109.2%  
Price / Book Value ratio x14.01.7 822.7%  
Dividend payout %08.8 0.0%   
Avg Mkt Cap Rs m23,988449,332 5.3%   
No. of employees `0001.66.8 22.8%   
Total wages/salary Rs m1,60519,881 8.1%   
Avg. sales/employee Rs Th3,040.215,535.6 19.6%   
Avg. wages/employee Rs Th1,029.22,905.4 35.4%   
Avg. net profit/employee Rs Th-3.37,482.5 -0.0%   
INCOME DATA
Net Sales Rs m4,740106,310 4.5%  
Other income Rs m922,595 3.5%   
Total revenues Rs m4,832108,906 4.4%   
Gross profit Rs m-13051,599 -0.3%  
Depreciation Rs m1014,773 2.1%   
Interest Rs m029,783 0.0%   
Profit before tax Rs m-13919,638 -0.7%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m5-28,764 -0.0%   
Profit after tax Rs m-551,203 -0.0%  
Gross profit margin %-2.748.5 -5.6%  
Effective tax rate %-3.7-146.5 2.5%   
Net profit margin %-0.148.2 -0.2%  
BALANCE SHEET DATA
Current assets Rs m2,726118,154 2.3%   
Current liabilities Rs m2,435462,260 0.5%   
Net working cap to sales %6.1-323.7 -1.9%  
Current ratio x1.10.3 438.1%  
Inventory Days Days7427 277.5%  
Debtors Days Days4147 87.6%  
Net fixed assets Rs m1,035113,727 0.9%   
Share capital Rs m50361 13.9%   
"Free" reserves Rs m942264,093 0.4%   
Net worth Rs m1,716264,454 0.6%   
Long term debt Rs m0242,206 0.0%   
Total assets Rs m4,156726,834 0.6%  
Interest coverage xNM1.7-  
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x1.10.1 779.7%   
Return on assets %-0.111.1 -1.1%  
Return on equity %-0.319.4 -1.5%  
Return on capital %010.3 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m37515,110 2.5%   
Fx outflow Rs m4704,298 10.9%   
Net fx Rs m-9610,813 -0.9%   
CASH FLOW
From Operations Rs m-8-159,666 0.0%  
From Investments Rs m-146-17,677 0.8%  
From Financial Activity Rs m862186,503 0.5%  
Net Cashflow Rs m7099,364 7.6%  

Share Holding

Indian Promoters % 0.0 52.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.0 7.5%  
FIIs % 15.7 26.6 59.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 16.5 55.2%  
Shareholders   12,856 93,274 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  MERCK LTD  SHASUN PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, BOB-Vijaya-Dena Merger, and Top Stocks in Action Today(Pre-Open)

Share markets in India continued their momentum and ended in red yesterday. Sectoral indices traded in red, with stocks in the realty sector, power sector and PSU sector leading the losses.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - LUPIN LTD COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS